Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting

Authors :: François Paris
Philippe Hulin
Ariane Desselle
Tanguy Chaumette
Marie-Hélène Gaugler
Jacques Aubry
Julien Fleurence
Stéphane Birklé
Nolwenn Dubois
Denis Cochonneau
Centre de Recherche en Cancérologie Nantes-Angers (CRCNA)
Centre Hospitalier Universitaire d'Angers (CHU Angers)
PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes)
Institut de Radioprotection et de Sûreté Nucléaire (IRSN)
Source :: OncoImmunology, OncoImmunology, Taylor & Francis, 2013, 2 (4), pp.e23661. ⟨10.4161/onci.23661⟩, Oncoimmunology
Publication Year :: 2013
Publisher :: Informa UK Limited, 2013.
Abstract: International audience; Current antiangiogenic immunotherapeutic strategies mainly focus on the blockade of circulating cytokines or receptors that are overexpressed by endothelial cells. We proposed globotriaosylceramide (Gb3) as a viable alternative target for antiangiogenic therapies. In this setting, we developed an anti-Gb3 antibody and validated its therapeutic efficacy in metastatic tumor models. © 2013 Landes Bioscience.

Full Text Access

Tools